CA-NEXON-AMERICA-INC
5.6.2019 19:32:09 CEST | Business Wire | Press release
World-renowned MMORPG MapleStory announced today its highly anticipated Explorer Bowman class Pathfinder will be available to players on June 26 , with a pre-creation period starting June 12 . In the game’s update following the conclusion of the Black Mage storyline, players can explore the new Adventure Island events, take on a new theme dungeon, and level up faster with new characters via the Tera Burning Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005050/en/
Pathfinder pre-creation will start on June 12 and will allow players to choose their Pathfinder’s features such as gender, hair color, and more before rolling out their characters for play on June 26. From June 12 to July 23, players will also enjoy the Tera Burning Project , where one new character per account will gain the extraordinary ability to gain a total of three levels each time they level up!
Starting June 12, players can also participate in a number of engaging events in Adventure Island , including Adventure Bingo, Maplerunner, Reverse Battle, and more. Through these events, players can work on their Adventurer Tier and collect Adventure Coins to purchase new items in the Adventure Coin Shop.
The update also brings massive improvements to gameplay systems to help players of all levels. These improvements include refining tutorial and job advancement quests, improving rewards for low level theme dungeons, increasing meso drops in Reboot worlds, as well as lowering quest requirements for 5th Job advancement and improving Star Force success rates and Arcane Symbol improvement costs. Multiple jobs will also be getting skill revamps in order to improve their abilities as well as increase consistency across the various jobs. The new theme dungeon, Secret Forest of Elodin, will also be available for players level 30 to 59 to explore.
Players who visit the Return to Adventure event now through June 10 can earn the Adventure Microsite Gift Box by clicking on the “Get Gifts Now” button on the page. Those who participate in the Return to Adventure event can also receive additional gift boxes with tons of new and exclusive prizes on June 12.
For more details on the MapleStory Pathfinder update, visit http://bit.ly/bw-maplestory-pathfinder .
Assets :
Social Media:
About MapleStory
With 14 years of sustained gaming excellence, MapleStory remains a critically acclaimed classic MMORPG with millions of registered active players around the world. First released in North America in 2005, MapleStory has experienced memorable in-game events, over 274 million created characters, and still is the World’s Largest Online Adventure. For more information about the game, please visit http://maplestory.nexon.net .
About Nexon America Inc. http://www.nexon.net
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO) is a global leader in online games with more than 80 live games operated across more than 190 countries. Nexon America introduced micro-transactions and the free-to-play business model in 2005, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Nexon is listed on the Tokyo Stock Exchange, and the company was placed on the Nikkei Stock Index 300 in 2017.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005050/en/
Contact:
Media Contact Wahid Lodin B/HI for Nexon America wahid_lodin@bhimpact.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom